Cargando…

Initial therapeutic strategy of invasive candidiasis for intensive care unit patients: a retrospective analysis from the China-SCAN study

BACKGROUND: To investigate the impact of initial antifungal therapeutic strategies on the prognosis of invasive Candida infections (ICIs) in intensive care units (ICUs) in China. METHODS: A total of 306 patients with proven ICIs in the China-SCAN study were analyzed retrospectively. Empiric, pre-emp...

Descripción completa

Detalles Bibliográficos
Autores principales: Cui, Na, Wang, Hao, Su, Longxiang, Qiu, Haibo, Li, Ruoyu, Liu, Dawei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5260133/
https://www.ncbi.nlm.nih.gov/pubmed/28114898
http://dx.doi.org/10.1186/s12879-017-2207-1
_version_ 1782499350553821184
author Cui, Na
Wang, Hao
Su, Longxiang
Qiu, Haibo
Li, Ruoyu
Liu, Dawei
author_facet Cui, Na
Wang, Hao
Su, Longxiang
Qiu, Haibo
Li, Ruoyu
Liu, Dawei
author_sort Cui, Na
collection PubMed
description BACKGROUND: To investigate the impact of initial antifungal therapeutic strategies on the prognosis of invasive Candida infections (ICIs) in intensive care units (ICUs) in China. METHODS: A total of 306 patients with proven ICIs in the China-SCAN study were analyzed retrospectively. Empiric, pre-emptive, and targeted therapy were adopted based on starting criteria including clinical, microbiological, and other conventional prediction rules. The primary outcome was hospital mortality and the secondary endpoints were duration days in ICU and duration days in hospital. The global responses (clinical and microbiological) at the end of the empirical therapy were also assessed. RESULTS: A total of 268/306 (87.6%) ICI patients received antifungal therapy, including 142/268 (53.0%) initial empirical therapy, 53/268 (19.8%) initial pre-emptive therapy, and 73/268 (27.2%) initial targeted therapy. Compared with the initial empirical antifungal therapy and targeted antifungal therapy, patients with initial pre-emptive antifungal therapy had significantly less clinical remission [11/53 (21.2%) vs. 61/142 (43.3%) vs. 22/73 (30.1%), P = 0.009], higher ICU [26/53 (57.8%) vs. 42/142 (32.2%) vs. 27/73 (43.5%), P = 0.008] and hospital mortality [27/53 (60.0%) vs. 43/142 (32.8%) vs. 29/73 (46.8%), P = 0.004] and more microbiological persistence [9/53 (17.0%) vs. 6/142 (4.2%) vs. 9/73 (12.3%), P = 0.011]. Kaplan-Meier survival analysis revealed that ICI patients with initial pre-emptive antifungal therapy and targeted antifungal therapy were associated with reduced hospital duration compared with patients with initial empirical antifungal therapy after confirmation of fungal infection (log-rank test: P = 0.021). Multivariate regression analysis provided evidence that initial empirical antifungal therapy was an independent predictor for DECREASING the hospital mortality in ICI patients on ICU admission and at ICI diagnosis (odds ratio 0.327, 95% confidence interval 0.160–0.667, P = 0.002; odds ratio 0.351, 95% confidence interval 0.168–0.735, P = 0.006). CONCLUSIONS: The initial therapeutic strategy for invasive candidiasis was independently associated with hospital mortality. Prompt empirical antifungal therapy could be critical to decrease early hospital mortality. TRIAL REGISTRATION: Clinicaltrials.gov NCT01253954 (retrospectively registration date: December 3, 2010)
format Online
Article
Text
id pubmed-5260133
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-52601332017-01-30 Initial therapeutic strategy of invasive candidiasis for intensive care unit patients: a retrospective analysis from the China-SCAN study Cui, Na Wang, Hao Su, Longxiang Qiu, Haibo Li, Ruoyu Liu, Dawei BMC Infect Dis Research Article BACKGROUND: To investigate the impact of initial antifungal therapeutic strategies on the prognosis of invasive Candida infections (ICIs) in intensive care units (ICUs) in China. METHODS: A total of 306 patients with proven ICIs in the China-SCAN study were analyzed retrospectively. Empiric, pre-emptive, and targeted therapy were adopted based on starting criteria including clinical, microbiological, and other conventional prediction rules. The primary outcome was hospital mortality and the secondary endpoints were duration days in ICU and duration days in hospital. The global responses (clinical and microbiological) at the end of the empirical therapy were also assessed. RESULTS: A total of 268/306 (87.6%) ICI patients received antifungal therapy, including 142/268 (53.0%) initial empirical therapy, 53/268 (19.8%) initial pre-emptive therapy, and 73/268 (27.2%) initial targeted therapy. Compared with the initial empirical antifungal therapy and targeted antifungal therapy, patients with initial pre-emptive antifungal therapy had significantly less clinical remission [11/53 (21.2%) vs. 61/142 (43.3%) vs. 22/73 (30.1%), P = 0.009], higher ICU [26/53 (57.8%) vs. 42/142 (32.2%) vs. 27/73 (43.5%), P = 0.008] and hospital mortality [27/53 (60.0%) vs. 43/142 (32.8%) vs. 29/73 (46.8%), P = 0.004] and more microbiological persistence [9/53 (17.0%) vs. 6/142 (4.2%) vs. 9/73 (12.3%), P = 0.011]. Kaplan-Meier survival analysis revealed that ICI patients with initial pre-emptive antifungal therapy and targeted antifungal therapy were associated with reduced hospital duration compared with patients with initial empirical antifungal therapy after confirmation of fungal infection (log-rank test: P = 0.021). Multivariate regression analysis provided evidence that initial empirical antifungal therapy was an independent predictor for DECREASING the hospital mortality in ICI patients on ICU admission and at ICI diagnosis (odds ratio 0.327, 95% confidence interval 0.160–0.667, P = 0.002; odds ratio 0.351, 95% confidence interval 0.168–0.735, P = 0.006). CONCLUSIONS: The initial therapeutic strategy for invasive candidiasis was independently associated with hospital mortality. Prompt empirical antifungal therapy could be critical to decrease early hospital mortality. TRIAL REGISTRATION: Clinicaltrials.gov NCT01253954 (retrospectively registration date: December 3, 2010) BioMed Central 2017-01-23 /pmc/articles/PMC5260133/ /pubmed/28114898 http://dx.doi.org/10.1186/s12879-017-2207-1 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Cui, Na
Wang, Hao
Su, Longxiang
Qiu, Haibo
Li, Ruoyu
Liu, Dawei
Initial therapeutic strategy of invasive candidiasis for intensive care unit patients: a retrospective analysis from the China-SCAN study
title Initial therapeutic strategy of invasive candidiasis for intensive care unit patients: a retrospective analysis from the China-SCAN study
title_full Initial therapeutic strategy of invasive candidiasis for intensive care unit patients: a retrospective analysis from the China-SCAN study
title_fullStr Initial therapeutic strategy of invasive candidiasis for intensive care unit patients: a retrospective analysis from the China-SCAN study
title_full_unstemmed Initial therapeutic strategy of invasive candidiasis for intensive care unit patients: a retrospective analysis from the China-SCAN study
title_short Initial therapeutic strategy of invasive candidiasis for intensive care unit patients: a retrospective analysis from the China-SCAN study
title_sort initial therapeutic strategy of invasive candidiasis for intensive care unit patients: a retrospective analysis from the china-scan study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5260133/
https://www.ncbi.nlm.nih.gov/pubmed/28114898
http://dx.doi.org/10.1186/s12879-017-2207-1
work_keys_str_mv AT cuina initialtherapeuticstrategyofinvasivecandidiasisforintensivecareunitpatientsaretrospectiveanalysisfromthechinascanstudy
AT wanghao initialtherapeuticstrategyofinvasivecandidiasisforintensivecareunitpatientsaretrospectiveanalysisfromthechinascanstudy
AT sulongxiang initialtherapeuticstrategyofinvasivecandidiasisforintensivecareunitpatientsaretrospectiveanalysisfromthechinascanstudy
AT qiuhaibo initialtherapeuticstrategyofinvasivecandidiasisforintensivecareunitpatientsaretrospectiveanalysisfromthechinascanstudy
AT liruoyu initialtherapeuticstrategyofinvasivecandidiasisforintensivecareunitpatientsaretrospectiveanalysisfromthechinascanstudy
AT liudawei initialtherapeuticstrategyofinvasivecandidiasisforintensivecareunitpatientsaretrospectiveanalysisfromthechinascanstudy
AT initialtherapeuticstrategyofinvasivecandidiasisforintensivecareunitpatientsaretrospectiveanalysisfromthechinascanstudy